LONHALA MAGNAIR KIT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lonhala Magnair Kit, and when can generic versions of Lonhala Magnair Kit launch?
Lonhala Magnair Kit is a drug marketed by Sunovion Resp and is included in one NDA. There are thirteen patents protecting this drug.
This drug has eighty-two patent family members in fifteen countries.
The generic ingredient in LONHALA MAGNAIR KIT is glycopyrrolate. There are seventeen drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lonhala Magnair Kit
A generic version of LONHALA MAGNAIR KIT was approved as glycopyrrolate by AM REGENT on July 23rd, 1986.
Summary for LONHALA MAGNAIR KIT
| International Patents: | 82 |
| US Patents: | 13 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | LONHALA MAGNAIR KIT at DailyMed |
US Patents and Regulatory Information for LONHALA MAGNAIR KIT
LONHALA MAGNAIR KIT is protected by thirteen US patents.
Patents protecting LONHALA MAGNAIR KIT
Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Aerosol delivery device and method of operating the aerosol delivery device
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD OF USING AN AEROSOL DELIVERY DEVICE TO AEROSOLIZE GLYCOPYRROLATE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: LONG-TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Forming a perforate membrane by laser drilling and a subsequent electro-polishing step
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Inhalation therapy device
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Fluid droplet production apparatus and method
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Fluid droplet production apparatus and method
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Disposable ampoule for an aerosol generating device
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Aerosol therapy device
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Expired US Patents for LONHALA MAGNAIR KIT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sunovion Resp | LONHALA MAGNAIR KIT | glycopyrrolate | SOLUTION;INHALATION | 208437-001 | Dec 5, 2017 | See Plans and Pricing | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for LONHALA MAGNAIR KIT
See the table below for patents covering LONHALA MAGNAIR KIT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 60039902 | See Plans and Pricing | |
| World Intellectual Property Organization (WIPO) | 2004039442 | See Plans and Pricing | |
| European Patent Office | 3711797 | DISPOSITIF D'ADMINISTRATION D'AÉROSOL ET PROCÉDÉ DE FONCTIONNEMENT DU DISPOSITIF D'ADMINISTRATION D'AÉROSOL (AEROSOL DELIVERY DEVICE AND METHOD OF OPERATING THE AEROSOL DELIVERY DEVICE) | See Plans and Pricing |
| Russian Federation | 2008110067 | ИНГАЛЯТОРНОЕ ТЕРАПЕВТИЧЕСКОЕ УСТРОЙСТВО С АМПУЛОЙ ДЛЯ ХРАНЕНИЯ ПОДЛЕЖАЩЕГО РАСПЫЛЕНИЮ МЕДИКАМЕНТА | See Plans and Pricing |
| Canada | 2716936 | PROCEDE ET SYSTEME PERMETTANT DE TRAITER LA BRONCHOPNEUMOPATHIE CHRONIQUE OBSTRUCTIVE AU MOYEN D'ADMINISTRATIONS D'ANTICHOLINERGIQUES PAR NEBULISATION (METHOD AND SYSTEM FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED ANTICHOLINERGIC ADMINISTRATIONS) | See Plans and Pricing |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LONHALA MAGNAIR KIT
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2435025 | 19C1040 | France | See Plans and Pricing | PRODUCT NAME: COMBINAISON DE GLYCOPYRROLATE (Y COMPRIS TOUS SELS, ESTERS, ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI) ET DE FORMOTEROL (Y COMPRIS TOUS SELS, ESTERS, ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI); NAT. REGISTRATION NO/DATE: EU/1/18/1339 20181220; FIRST REGISTRATION: - EU/1/18/1339 20181220 |
| 2435025 | LUC00124 | Luxembourg | See Plans and Pricing | PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220 |
| 2435024 | 21C1020 | France | See Plans and Pricing | PRODUCT NAME: COMBINAISON DE FORMOTEROL (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI), GLYCOPYRROLATE (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI) ET BUDESONIDE (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI); REGISTRATION NO/DATE: EU/1/20/1498 20201210 |
| 2435025 | 2019C/532 | Belgium | See Plans and Pricing | PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI) ET DE FORMOTEROL (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220 |
| 2435024 | 2021C/518 | Belgium | See Plans and Pricing | PRODUCT NAME: UNE COMBINAISON DE FORMOTEROL (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), GLYCOPYRROLATE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET BUDESONIDE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1498 20201210 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2022 - 2023
NCE-1 Patent Challenge Dates 2022 - 2023
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2022, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
